New therapy enters trials

INO-8875, an Adenosine 1 agonist in Phase I testing for the treatment of glaucoma, has begun patient enrolment.

Related Content:

ArticlesGlaucoma
The relationship between myopia and conjunctival-scleral geometry
Opportunities lie ahead at the 39th ‘hybrid’ ESCRS
Ultra-widefield imaging improves visibility of retina and optic nerve in KPro patients